Analyst Reco. FUSN PHAR

Equities

FUSN

CA36118A1003

Market Closed - Nasdaq Other stock markets 01:30:00 27/04/2024 am IST			5-day change	1st Jan Change
21.42 ^USD	+0.09%		+0.75%	+122.89%

16/04	TD Cowen Downgrades Fusion Pharmaceuticals to Hold	MT
09/04	Fusion Pharmaceuticals Inc. Presents Interim Efficacy and Safety Data from the Phase 2 TATCIST Open-Label Clinical Trial Evaluating FPI-2265	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

TD Cowen Downgrades Fusion Pharmaceuticals to Hold	16/04	MT
B. Riley Downgrades Fusion Pharmaceuticals to Neutral From Buy on Heels of Announced Sale to AstraZeneca, Adjusts PT to $23 From $13	20/03	MT
Bloom Burton Downgrades Fusion Pharmaceuticals to Hold From Buy, Raises Price Target to $21.50 From $20	20/03	MT
Fusion Pharmaceuticals Downgraded by RBC to Sector Perform From Outperform, Speculative Risk Removed, Price Target Raised to $21 From $16	20/03	MT
JonesTrading Downgrades Fusion Pharmaceuticals to Hold From Buy	20/03	MT
Jefferies Downgrades Fusion Pharmaceuticals to Hold From Buy, Raises Price Target to $21 From $10	20/03	MT
Morgan Stanley Downgrades Fusion Pharmaceuticals to Equalweight From Overweight, Raises Price Target to $21 From $10	20/03	MT
Truist Securities Downgrades Fusion Pharmaceuticals to Hold From Buy, Adjusts Price Target to $21 From $11	19/03	MT
William Blair Downgrades Fusion Pharmaceuticals to Market Perform From Outperform	19/03	MT
Raymond James Downgrades Fusion Pharmaceuticals to Market Perform From Strong Buy, Raises Price Target to $21 From $16	19/03	MT
Brookline Capital Downgrades Fusion Pharmaceuticals to Hold From Buy, Raises Price Target to $21 From $20	19/03	MT
Wedbush Downgrades Fusion Pharmaceuticals to Neutral From Outperform on Heels of Announced Sale to AstraZeneca, Adjusts PT to $24 From $13	19/03	MT
Leerink Downgrades Fusion Pharmaceuticals to Market Perform From Outperform, Lifts Price Target to $21 From $17	19/03	MT
RBC Lifts Price Target on Fusion Pharmaceuticals to $16 From $12, Sees 80% Probability of Upside, Protected Downside; Outperform, Speculative Risk Kept	04/03	MT
Oppenheimer Ups Price Target on Fusion Pharmaceuticals to $15 From $13, Maintains Outperform Rating	05/01	MT
Raymond James Upgrades Fusion Pharmaceuticals to Strong Buy From Outperform, Boosts Price Target to $15 From $12	27/12	MT
Fusion Pharmaceuticals Initiated at Outperform, Speculative Risk by RBC; Price Target Set at $12 Amid Bullish View on Radiopharmaceuticals	20/12	MT
Oppenheimer Starts Fusion Pharmaceuticals at Outperform With $13 PT, Sees as Leading Player in Targeted Radiopharmaceutical Therapy Space	29/23/29	MT
Raymond James Adjusts Fusion Pharmaceuticals' Price Target to $12 From $13, Keeps Outperform Rating	28/23/28	MT
Raymond James Initiates Fusion Pharmaceuticals at Outperform Rating With $13 Price Target	23/23/23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. FUSN PHAR

Equities

FUSN

CA36118A1003

Analyst Reco.

Filters